(Q39845394)

English

Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C P Coyne

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Matt K Ross

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

John G Bailey

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

1 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Journal of Drug Targeting

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

474-489

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Her-2/neu and breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Ongoing phase I and II studies of novel anthracyclines

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Alternative intracellular routing of ErbB receptors may determine signaling potency

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1080%2F10611860903012802

21 January 2018

Identifiers

10.1080/10611860903012802

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39845394&oldid=2091399619"